Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Wendys Co (WEN) Price & Performance

Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Wendys Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.34 (market cap $505.73M), while Wendys Co trades at $8.46 (market cap $1.44B). The key difference: Wendys Co is far larger — about 2.8× Ginkgo Bioworks Holdings Inc's market cap, and Wendys Co pays a 3.71% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

DNAWEN
Market Cap
$505.73M$1.44B
Sector
HealthConsumer Cyclical
52-Week High
$16.14$10.68
52-Week Low
$5.48$6.17
Enterprise Value
$607.68M$5.17B
Dividend Yield
3.71%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.

The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.

Wendys Co

WEN trades at $8.595, up 17.74% in 24 hours, with a neutral technical signal. Recent Q2 2026 EPS of $0.18 beat expectations, but revenue trends are flat and net income margin declined to 5.72% in 2025. The company cut its dividend and withdrew 2026 guidance amid a strategic turnaround under new leadership, facing traffic declines and loss of its No. 2 U.S. burger chain position to Burger King.

Outlook is cautious; the dividend cut frees cash for restructuring, but execution risks are high. Valuation appears reasonable with a P/E of 11.44, though high debt and competitive pressures pose significant headwinds. Analyst consensus is mixed, with 62.75% hold ratings reflecting uncertainty around the turnaround plan's success.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About Wendys Co

The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.

Read more on WEN